

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms

NCT07121998

Status RECRUITING
Sponsor Uppsala University
Enrollment 94 participants

Key Eligibility Criteria

Inclusion (4)

- Informed consent
- Age ≥18 years
- Histopathology confirmed endocrine neoplasm
- Treatment with alkylating chemotherapy: Arm A; about to start alkylating chemotherapy, or Arm B; at disease progression or recurrence with previous alkylating chemotherapy treatment.

Exclusion (3)

- If planned tissue biopsy: risk factors for biopsy-related complications accordingly to local investigator, including coagulation disorder
- Long term treatment with anticoagulant that cannot be temporarily paused without unacceptable risk
- Pregnancy

Locations (1 total)

Akademiska Sjukhuset, Uppsala, Sweden